07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

Alphanate update

Grifols launched the SPIRIT registry to evaluate Alphanate in 100 patients with hemophilia A and inhibitors. Alphanate is approved in the U.S. to treat hemophilia A, congenital von Willebrand disease (vWD) and for use in...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Clinical News

Alphanate regulatory update

FDA approved an updated label for Grifols' Alphanate antihemophilic factor/ von Willebrand factor (vWF) complex to include that certain manufacturing steps have been shown to reduce the infectivity of an experimental transmissible spongiform encephalitis (TSE)...
08:00 , Feb 12, 2007 |  BC Week In Review  |  Clinical News

Alphanate regulatory update

FDA approved an sBLA for Alphanate antihemophilic factor/ von Willebrand factor complex for patients undergoing surgery or invasive procedures with von Willebrand disease (vWD) in whom desmopressin is either ineffective or contraindicated. Alphanate is approved...
08:00 , Feb 5, 2007 |  BC Week In Review  |  Clinical News

Alphanate regulatory update

FDA approved Alphanate, an antihemophilic factor/ von Willebrand factor complex, to treat congenital von Willebrand disease (VWD). Grifols S.A. , Barcelona, Spain   Product: Alphanate   Business: Hematology  ...
08:00 , Nov 8, 1999 |  BioCentury  |  Tools & Techniques

Approved protein & antibody therapeutics

Approved protein & antibody therapeutics...